Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 486.5 INR 1.75% Market Closed
Market Cap: 1.2T INR
Have any thoughts about
Cipla Ltd?
Write Note

Cipla Ltd
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipla Ltd
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Cipla Ltd
NSE:CIPLA
Non-Reccuring Items
-â‚ą1.9B
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Non-Reccuring Items
â‚ą987m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Non-Reccuring Items
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Non-Reccuring Items
-â‚ą82.6m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cipla Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals

Cipla Ltd. stands as a prominent player in the global pharmaceutical landscape, rooted in its founding vision of accessible healthcare for all. Established in 1935 in India, the company has evolved from its initial focus on producing affordable medicines to becoming a leading provider of generic and specialty pharmaceuticals, over-the-counter products, and active pharmaceutical ingredients (APIs). With a strong commitment to innovation, Cipla allocates a significant portion of its resources to research and development, leading to a robust pipeline of patented and life-saving treatments, particularly in the fields of respiratory, HIV/AIDS, and oncology therapies. This focus on both global markets and local needs has positioned Cipla not only as a trusted brand in India but also as a key player in over 80 countries worldwide. For investors, Cipla represents a compelling opportunity due to its strategic initiatives aimed at sustaining growth amidst challenging market dynamics. The company's impressive financial performance, characterized by steady revenue growth and healthy margins, underscores its operational efficiency and market-leading position. Cipla’s proactive approach to collaborations, licensing agreements, and technological advancements indicates a future that embraces pharmaceutical innovations while maintaining cost-effective solutions. Furthermore, its commitment to sustainability and ethical practices resonates well in today's socially conscious investing landscape. As healthcare demands continue to rise globally, Cipla's mission to enhance access to vital medications stands to benefit both patients and shareholders alike.

CIPLA Intrinsic Value
1 173.46 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Cipla Ltd's Non-Reccuring Items?
Non-Reccuring Items
-1.9B INR

Based on the financial report for Sep 30, 2024, Cipla Ltd's Non-Reccuring Items amounts to -1.9B INR.

What is Cipla Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-16%

Over the last year, the Non-Reccuring Items growth was -7%. The average annual Non-Reccuring Items growth rates for Cipla Ltd have been -16% over the past three years .

Back to Top